Is PT-141 (Bremelanotide) Legal in Oregon? How to Access It Legally

HealthRX.com

Bremelanotide is legal only as prescription Vyleesi

1.75 mgLabel dose per injection, given subcutaneously as neededSource: dailymed.nlm.nih.gov

Print or save as PDF

Key numbers

  • 45 minutesMinimum wait before anticipated sexual activity to inject a doseSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 40.0%Share of treated patients reporting nausea (vs 1.3% on placebo)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.75 mgLabel dose per injection, given subcutaneously as neededSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Bremelanotide

  • FDA status / Approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
  • Current label holder / Cosette Pharmaceuticals [1]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Form / 1.75 mg subcutaneous autoinjector, prescription only [1]
  • Not indicated for / Men, postmenopausal women, enhanced sexual performance [1]
  • Compounded and research 'PT-141' / Not Vyleesi, not FDA-approved drugs [3][1]
  • FDA bulk-substance lists / Bremelanotide does not appear [4][5]
  • Oregon-specific rules / None cited; federal status described

What PT-141 is

PT-141 is the research name for bremelanotide, a cyclic peptide of seven amino acids that activates melanocortin receptors in the potency order MC1R, MC4R, MC3R, MC5R, MC2R. At the approved dose, binding at MC1R and MC4R is most relevant, and how that improves desire is unknown [1].

FDA approved it as Vyleesi under NDA 210557 on June 21, 2019; the current label holder is Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous injection given from a prefilled autoinjector, and it is prescription only [1].

The indication is narrow: premenopausal women with acquired, generalized hypoactive sexual desire disorder, meaning low desire that causes marked distress or interpersonal difficulty and is not due to a medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label says it is not indicated for postmenopausal women or for men, and not to enhance sexual performance [1].

The Oregon question

Bremelanotide is FDA-approved as the prescription-only product Vyleesi [1][2]. That federal status is what this page describes; no Oregon-specific rule on bremelanotide prescribing, telehealth or dispensing is cited here.

Questions worth asking

Choose the questions you want to keep

Compounded and 'research use only' PT-141

Products sold as PT-141 by compounding pharmacies, and vials labelled for research use, are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1].

Two federal facts are relevant. Bremelanotide does not appear on FDA's lists of bulk drug substances for compounding, including the list of substances that may present significant safety risks, a page dated April 22, 2026 [4][5]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [6].

HealthRX.com offers PT-141 by prescription.

How a prescription is used

The label dose is 1.75 mg injected subcutaneously into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours. More than 8 doses per month is not recommended, and the label says to stop after 8 weeks if symptoms have not improved [1].

Use in men or in postmenopausal women would be off-label. FDA's position is that once a drug is approved, prescribers generally may prescribe it for an unapproved use when they judge it medically appropriate for their patient [7]; the label itself limits the indication as described above [1].

What the label says to watch

Each dose causes a transient rise in blood pressure and a drop in heart rate. In clinical studies the maximal increases were 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate reduced by up to 5 beats per minute and values usually back to baseline within 12 hours [1]. In an 8-day ambulatory study of 127 premenopausal women, mean daytime increases were 1.9 mmHg systolic and 1.7 mmHg diastolic [1]. Vyleesi is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease [1].

Nausea was reported by 40.0% of treated patients versus 1.3% on placebo; 13% used an anti-nausea medicine and 8% stopped the trials because of it [1]. Flushing (20.3%), injection site reactions (13.2%) and headache (11.3%) were the next most common reactions [1]. Focal hyperpigmentation, including the face, gums and breasts, was reported by 1% of patients taking up to 8 doses a month versus none on placebo [1]. The label advises effective contraception and stopping Vyleesi if pregnancy is suspected [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. How soon before anticipated sexual activity does the label say to inject the 1.75 mg dose?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is PT-141 (bremelanotide) legal in Oregon?
Under federal law, bremelanotide is available as Vyleesi, an FDA-approved, prescription-only product [1][2]. No Oregon-specific rule is cited on this page. Vials sold as research chemicals are not FDA-approved drugs [3].
Do I need a prescription for PT-141?
Yes. Bremelanotide is prescription only as an FDA-approved product and is not sold over the counter [1].
Is compounded PT-141 the same as Vyleesi?
No. Compounded and research-use bremelanotide products are not Vyleesi or FDA-approved drugs, and compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [3][1]. Bremelanotide also does not appear on FDA's bulk-substance lists for compounding [4][5].
Can a man or a postmenopausal woman get a bremelanotide prescription?
The label covers only premenopausal women with acquired, generalized HSDD and states it is not indicated for men or postmenopausal women [1]. Off-label prescribing is a prescriber's judgment; FDA says prescribers generally may prescribe an approved drug for an unapproved use when they judge it medically appropriate [7].
What is the approved dose of bremelanotide?
1.75 mg subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours [1]. More than 8 doses per month is not recommended [1].
What are the most common side effects?
In pooled phase 3 trials, nausea occurred in 40.0% of treated patients versus 1.3% on placebo, flushing in 20.3% versus 0.3%, and headache in 11.3% versus 1.9% [1]. Focal hyperpigmentation was reported by 1% of patients taking up to 8 doses a month [1].
Show all 7 referencesHide references
PT-141 Oregon: evidence summary chart
Image: HealthRX.com. Full PT-141 Oregon guide and sources at healthrx.com/peptide-legal-pt-141.